Managing AUD and Liver Disease Workshop Module 3

Print Friendly, PDF & Email

         

Session 3: Initiating therapy including considerations for pharmacotherapy, behavioural therapy, comorbid mental health conditions (e.g. depression, anxiety, sleep disturbance) and poly-substance use

By the end of this session, participants will be able to:

  1. Describe the risks and benefits of selected anti-craving pharmacotherapies and positively impact their intention to prescribe these agents in practice.
  2. Describe the advantages of concurrent behavioural and pharmacological therapies
  3. Discuss first line therapies for concurrent anxiety, depression or sleep disturbance in patients with alcohol use disorder and liver disease.
  4. Explain the nuances of treating alcohol use disorder in unique populations (e.g. poly-substance use, geriatrics, and people experiencing homelessness).

Instructions

The following must be completed to receive your certificate:

  • Pre-survey (linked below)
  • Watch the Video below
  • Attend the live session
  • Complete the post-survey which will be emailed to you four weeks after the live session

Step 1: Complete the pre-survey

Click here to take the survey
You will be redirected to this page once you complete the survey.

Step 2: Watch the video

Step 3: Attend the live session

February 3rd, 2022
6:30-7:30pm MST

Join Zoom Meeting 
Meeting ID: 830 4332 6974 Passcode: 066863

Additional resources

Definition of Addiction – American Society of Addiction Medicine 

Rat Park 

Motivational Interviewing – Alcohol Video

Helping Patients Who Drink Too Much: A Clinicians Guide

Screening and Assessment Tools Resource

The Alcohol, Smoking and Substance Involvement Screening Test

SBIRT in Action Video

Retention Toolkit: Free MI Resource

Canadian Resources

Canada’s Low Risk Drinking Guidelines

Guidelines for Healthcare Providers to Promote Low Risk Drinking Guidelines

Alcohol in Canada: Canadian Centre on Substance Use and Addiction

Substance Use Treatment Centres for First Nations and Inuit

211.ca

Practical Approach to Substance Use Disorders for the Family Physicians

Canadian Alcohol Use Disorder Society

Alberta Resources

Find Day Treatment and Detox

Alberta Addiction Treatment Directory

Recovery Access Alberta: Treatment directory for patients and providers

Recovery Access Alberta: Alberta College of Family Physicians Tools for Practice

Alcoholics Anonymous Meetings Alberta

Smart Recovery Alberta

Recovery Dharma Alberta: Using Buddhist Practices

Recovery College: Free access to courses focusing on developing awareness and resourcefulness to help individuals and their loves ones through recovery

United States Resources

Substance Use and Mental Health Services Administration

National Institute on Drug Abuse

US Preventative Services Task Force: Alcohol

National Institute on Alcohol Abuse and Alcoholism

Further Reading

High Performance Healthcare: Using the Power of Relationships to Achieve Quality, Efficiency and Resilience

Healthcare Teamwork: Interprofessional Practice and Education

Beyond the Checklist: What Else Healthcare Can Learn from Aviation Teamwork and Safety

A Definition and Approach To Motivational Interviewing

NIAAA Treatment Navigator

Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders

Talking with Your Adult Patients about Alcohol, Drug, and/or Mental Health Problems: A Discussion for Primary Care Providers

Motivational Interviewing: Helping People Change

Feeling Good: The New Mood Therapy

The Feeling Good Handbook

Beyond Addiction: How Science and Kindness Help People Change

Accreditation Statement

This 2 credit per hour Group Learning activity has been certified by the National Office of the College of Family Physicians of Canada for up to 3 credits for each session. Mainpro+ participants may also earn additional certified credits by completing a Linking Learning exercise.

This event is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by The University of Calgary – Office of Continuing Medical Education and Professional Development. You may claim a maximum of 1.5 hours for each of the three sessions (credits are automatically calculated).

References

  1. Cron DC et al. American journal of transplantation. 2016 Jun;16(6):1805-11
    Corruble E et al. Journal of psychosomatic research. 2011 Jul 1;71(1):32-7
  2. DiMartini A et al. American Journal of Transplantation. 2011 Jun;11(6):1287-95
    Konerman MA, et al. BMJ Open Gastro. 2019 Apr 1;6(1):e000271
  3. Peng JK et al. Palliative medicine. 2019 Jan;33(1):24-36
  4. Hasin DS et al. Archives of general psychiatry. 2007 Jul 1;64(7):830-42
  5. Likhitsup A et al. Clinical Transplantation. 2021 Apr 7:e14312
  6. Dimartini A et al. Psychosomatics. 2004 Nov 1;45(6):517-23
  7. Mellinger JL et al. Alcoholism: Clinical and Experimental Research. 2019 Feb;43(2):334-41
  8. Leggio L, Lee MR. The American Journal of Medicine. 2017;130:124-134  Addolorato G et al. Journal of Hepatology. 2016 Sep 1;65(3):618-30
  9. Roesner S et al. Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews. 2010(9)  Kranzler HR, Van Kirk J. Alcohol Clin Exp Res. 2001 Sep;25(9):1335-41
  10. Streeton C, Whelan G. Alcohol Alcohol. 2001 Nov-Dec;36(6):544-52.  Bertolotti M et al. Journal of hepatology. 1997 Sep 1;27(3):505-11.
  11. Leggio L, Lee MR. The American Journal of Medicine. 2017;130:124-134  Addolorato G et al. Journal of Hepatology. 2016 Sep 1;65(3):618-30.
  12. Mellinger JL et L. Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic. Journal of Substance Abuse Treatment. 2021 Nov 1;130:108396.
  13. Winder GS et al. Best Practice & Research Clinical Gastroenterology. 2020 Sep 14:101685.
  14. Drumright LN et al. Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention. Journal of hepatology. 2011 Jul 1;55(1):45-52
  15. Erim Y et al. Feasibility and Acceptability of an Alcohol Addiction Therapy Integrated in a Transplant Center for Patients Awaiting Liver Transplantation. Alcohol. 2015; 51 (1):40–6
  16. Weinrieb RM et al. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver transplantation. 2011 May;17(5):539-47
  17. Schneekloth T et al. Impact of Pre-and Post-liver Transplant Addiction Treatment and AA Attendance on Outcomes for Recipients with Alcoholic Liver Disease. J Psychosomatic Res. 2018; 109:134
  18. Louvet A et al. Hepatology. 2017 Nov;66(5):1464-73
  19. Rehm J et al. Drug and alcohol review. 2010 Jul;29(4):437-45.
  20. Weinrieb RM et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics. 2001; 42 (2):110–6
  21. Georgiou G et al. First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transplant. 2003; 9 (7):772–5
  22. Anton RF et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3;295(17):2003-17
  23. Anton RF, et al. Journal of clinical psychopharmacology. 2005 Aug 1;25(4):349-57.
  24. Mellinger JL et L. Feasibility and early experience of a novel multidisciplinary alcohol-associated liver disease clinic. Journal of Substance Abuse Treatment. 2021 Nov 1;130:108396.
  25. Sliedrecht W, de Waart R, Witkiewitz K, Roozen HG. Alcohol use disorder relapse factors: A systematic review. Psychiatry research. 2019 Aug 1;278:97-115
  26. Miller MB, Donahue ML, Carey KB, Scott-Sheldon LA. Insomnia treatment in the context of alcohol use disorder: a systematic review and meta-analysis. Drug and alcohol dependence. 2017 Dec 1;181:200-7.
  27. Verma M and Winder GS 2021, submitted
  28. Sedky K et al General hospital psychiatry. 2012 Jan 1;34(1):53-61  Lucena MI et al. Expert opinion on drug safety. 2003 May 1;2(3):249-62  Selim K, Kaplowitz N. Hepatology. 1999 May;29(5):1347-51
  29. Mauri MC et al. Pharmacokinetics of antidepressants in patients with hepatic impairment. Clin Pharmacokinet. 2014;53(12):1069-1081.
  30. DeSanty KP, Amabile CM. Annals of Pharmacotherapy. 2007 Jul;41(7-8):1201-11.  Selim K, Kaplowitz N. Hepatology. 1999 May;29(5):1347-51.
  31. Lucena MI et al. Expert opinion on drug safety. 2003 May 1;2(3):249-62  livertox.nlm.nih.gov
  32. Rettman KS, McClintock C. Hepatotoxicity after short-term trazodone therapy. Annals of Pharmacotherapy. 2001 Dec;35(12):1559-61
  33. Wu T et al. Case report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease. Medicine. 2021;100(25):e26243  Fourman LT, Robert Meyer B. Autoimmune hepatitis in association with ramelteon. J Clin Gastroenterol 2013; 47: 651-4
  34. Boommersbach TJ et al. Mayo Clinic Proceedings 2015 May 1 (Vol. 90, No. 5, pp. 659-666). Elsevier  Miller S. The ASAM principles of addiction medicine. Lippincott Williams & Wilkins; 2018 Nov 26.
  35. Dionisi T et al.. Alcohol and Alcoholism. 2020 Aug 14;55(5):547-53
  36. Fentress TS et al. Experimental and Clinical Psychopharmacology. 2021 Jun;29(3):261.